UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial

Hematological oncology, 2019-06, Vol.37 (S2), p.65-66

2019

Volltextzugriff (PDF)

PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH R/R CLL OR SLL INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.216-217

2019

Volltextzugriff (PDF)

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

Hematological oncology, 2019-06, Vol.37 (S2), p.213-214

2019

Volltextzugriff (PDF)

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.214-216

2019

Volltextzugriff (PDF)

In silico insights into potential gut microbial modulation of NAD+ metabolism and longevity

Journal of biochemical and molecular toxicology, 2021-12, Vol.35 (12), p.e22925-n/a

2021

Volltextzugriff (PDF)

Pricing of Initial Audit Engagements by Large and Small Audit Firms

Contemporary accounting research, 2006-07, Vol.23 (2), p.333-368

2006

Volltextzugriff (PDF)

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.400-401

2019

Volltextzugriff (PDF)

Matching Adjusted Indirect Comparison (MAIC) Analysis For Ponatinib Vs Bosutinib In Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Value in health, 2016-11, Vol.19 (7), p.A577-A577

2016

Volltextzugriff (PDF)

PSY14 - Matching Adjusted Indirect Comparison (MAIC) Analysis For Ponatinib Vs Bosutinib In Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Value in health, 2016-11, Vol.19 (7), p.A577-A577

2016

Volltextzugriff (PDF)

P1.01-005 Overall Survival (OS) After Disease Progression (PD) on Brigatinib in Patients With Crizotinib-Refractory ALK+ NSCLC in ALTA

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1893-S1894

2017

Volltextzugriff (PDF)

1256 Phase I trial of oral Deforolimus in combination with Bevacizumab in patients with advanced solid tumours

European journal of cancer supplements, 2009, Vol.7 (2), p.137-137

2009

Volltextzugriff (PDF)

Indirect Comparison Of Efficacy Of PonatiniB Versus Bosutinib In 3rd-Line Chronic-Phase Chronic Myeloid Leukemia Using Iterative Proportional Fitting

Value in health, 2016-05, Vol.19 (3), p.A137-A137

2016

Volltextzugriff (PDF)

PCN21 - Indirect Comparison Of Efficacy Of PonatiniB Versus Bosutinib In 3rd-Line Chronic-Phase Chronic Myeloid Leukemia Using Iterative Proportional Fitting

Value in health, 2016-05, Vol.19 (3), p.A137-A137

2016

Volltextzugriff (PDF)

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

Hematological oncology, 2019-06, Vol.37 (S2), p.400-401

2019

Volltextzugriff (PDF)

PS1160 PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL

HemaSphere, 2019-06, Vol.3 (S1), p.526-527

2019

Volltextzugriff (PDF)

Maintained Reduction of Intraocular Pressure by Prostaglandin F2α-1-Isopropyl Ester Applied in Multiple Doses in Ocular Hypertensive and Glaucoma Patients

Ophthalmology (Rochester, Minn.), 1989-09, Vol.96 (9), p.1329-1337

1989

Volltextzugriff (PDF)

PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

HemaSphere, 2019-06, Vol.3 (S1), p.525-n/a

2019

Volltextzugriff (PDF)

Metabolite Predictors of HOMA in At‐Risk for Mobility Disability Elderly Subjects

The FASEB journal, 2013-04, Vol.27 (S1)

2013

Volltextzugriff (PDF)

Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6518-6518

2011

Volltextzugriff (PDF)

Does mitochondrial oxidative stress limit skeletal muscle function?

The FASEB journal, 2008-03, Vol.22 (S1)

2008

Volltextzugriff (PDF)

Influence of Treatment Protocol on the Long-Term Efficacy of Argon Laser Trabeculoplasty

Journal of glaucoma, 1993, Vol.2 (1), p.7-12

1993

Volltextzugriff (PDF)

Segmental Analysis of Computerized Optic Nerve Head Imaging

Journal of glaucoma, 1994, Vol.3 (3), p.232-236

1994

Volltextzugriff (PDF)

The effect of insider trading on financial analysts' forecast accuracy and dispersion

Journal of accounting and public policy, 1998, Vol.17 (4), p.311-327

1998

Volltextzugriff (PDF)

MnSOD deficiency results in elevated oxidative stress and decreased mitochondrial function but does not lead to muscle atrophy during aging: Increased mitochondrial oxidative stress does not lead to muscle atrophy

Aging cell, 2011-06, Vol.10 (3), p.493-505

2011

Volltextzugriff (PDF)

Financial analysts' earnings forecasts and insider trading

Journal of accounting and public policy, 1995-10, Vol.14 (3), p.233-261

1995

Volltextzugriff (PDF)

1 – 25 von 617

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(373)
Mit Volltextzugriff
(492)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Social Sciences
(60)
Business & Economics
(44)
Business
(31)
Humans
(30)
Banking Industry
(24)
Regulation Of Financial Institutions
(18)
Biological And Medical Sciences
(17)
Female
(15)
Male
(14)
Hematology, Oncology And Palliative Medicine
(13)
Manycompanies
(13)
National Security
(13)
Financial Services
(11)
Laws, Regulations And Rules
(11)
Medical Sciences
(11)
Northern America
(11)
Ratings & Rankings
(11)
U.S
(11)
Bank Holding Companies
(10)
Financial Services Modernization Act 1999-Us
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Fortune
(51)
Blood
(38)
Banking & Financial Services Policy Report
(22)
Journal Of Clinical Oncology
(21)
Clinical Lymphoma, Myeloma And Leukemia
(17)
Fortune International
(13)
Heart Rhythm
(13)
The American Banker
(13)
Modern Law Review
(12)
Intelligence And National Security
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial

PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH R/R CLL OR SLL INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

In silico insights into potential gut microbial modulation of NAD+ metabolism and longevity

Pricing of Initial Audit Engagements by Large and Small Audit Firms

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

Matching Adjusted Indirect Comparison (MAIC) Analysis For Ponatinib Vs Bosutinib In Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)

PSY14 - Matching Adjusted Indirect Comparison (MAIC) Analysis For Ponatinib Vs Bosutinib In Third-Line Chronic Phase Chronic Myeloid Leukemia (CP-CML)

P1.01-005 Overall Survival (OS) After Disease Progression (PD) on Brigatinib in Patients With Crizotinib-Refractory ALK+ NSCLC in ALTA

1256 Phase I trial of oral Deforolimus in combination with Bevacizumab in patients with advanced solid tumours

Indirect Comparison Of Efficacy Of PonatiniB Versus Bosutinib In 3rd-Line Chronic-Phase Chronic Myeloid Leukemia Using Iterative Proportional Fitting

PCN21 - Indirect Comparison Of Efficacy Of PonatiniB Versus Bosutinib In 3rd-Line Chronic-Phase Chronic Myeloid Leukemia Using Iterative Proportional Fitting

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL

PS1160 PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL

Maintained Reduction of Intraocular Pressure by Prostaglandin F2α-1-Isopropyl Ester Applied in Multiple Doses in Ocular Hypertensive and Glaucoma Patients

PS1157 EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL

Metabolite Predictors of HOMA in At‐Risk for Mobility Disability Elderly Subjects

Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies

Does mitochondrial oxidative stress limit skeletal muscle function?

Influence of Treatment Protocol on the Long-Term Efficacy of Argon Laser Trabeculoplasty

Segmental Analysis of Computerized Optic Nerve Head Imaging

The effect of insider trading on financial analysts' forecast accuracy and dispersion

MnSOD deficiency results in elevated oxidative stress and decreased mitochondrial function but does not lead to muscle atrophy during aging: Increased mitochondrial oxidative stress does not lead to muscle atrophy

Financial analysts' earnings forecasts and insider trading

Aktive Filter

Suchergebnisse filtern